- $20.09m
- $21.82m
- $0.02m
- 48
- 39
- 11
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.74 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 46.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.81% | ||
| Return on Equity | -8.64% | ||
| Operating Margin | -102.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.08 | 0.4 | 0.2 | 0.04 | 0.02 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Company’s patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 23rd, 1998
- Public Since
- November 6th, 2000
- No. of Shareholders
- 298
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 956,530,100
- Address
- 5051 Peachtree Corners Circle, NORCROSS, 30092
- Web
- https://www.findit.com/
- Phone
- +1 4044433224
- Auditors
- BF Borgers CPA PC
Upcoming Events for BRGX
Q3 2024 BioRegenx Inc Earnings Release
Similar to BRGX
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the BioRegenx share price?
As of Today at 19:37 UTC, shares in BioRegenx are trading at $0.03. This share price information is delayed by 15 minutes.
How has the BioRegenx share price performed this year?
Shares in BioRegenx last closed at $0.03 and the price had moved by -22.69% over the past 365 days. In terms of relative price strength the BioRegenx share price has underperformed the S&P500 Index by -35.12% over the past year.
What are the analyst and broker recommendations for BioRegenx?
There is no consensus recommendation for this security.
What is the BioRegenx dividend yield?
BioRegenx does not currently pay a dividend.
Does BioRegenx pay a dividend?
BioRegenx does not currently pay a dividend.
When does BioRegenx next pay dividends?
BioRegenx does not currently pay a dividend.
How do I buy BioRegenx shares?
To buy shares in BioRegenx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioRegenx?
As of the previous close price of $0.03, shares in BioRegenx had a market capitalisation of $29.65m.
Where are BioRegenx shares listed?
Here are the trading details for BioRegenx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BRGX
What kind of share is BioRegenx?
Based on an overall assessment of its quality, value and momentum BioRegenx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioRegenx share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the BioRegenx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioRegenx. Over the past six months, its share price has outperformed the S&P500 Index by +92.94%.
As of the last closing price of $0.03, shares in BioRegenx were trading -25.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioRegenx PE Ratio?
The BioRegenx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioRegenx?
BioRegenx's management team is headed by:
- Darrell Figg - PRE
- Oso Neal - CEO
- John Spicer - TRS
- Todd Davis - DRC